Forskning ved Københavns Universitet - Københavns Universitet

Forside

Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6

Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

  • Peter Iversen
  • Jan-Erik Johansson
  • Pär Lodding
  • Olavi Lukkarinen
  • Per Lundmo
  • Peter Klarskov
  • Teuvo L J Tammela
  • Ilker Tasdemir
  • Tom Morris
  • Kevin Carroll
  • Scandinavian Prostatic Cancer Group
We evaluated the benefits of adding 150 mg bicalutamide to standard care, that is radical prostatectomy, radiotherapy or watchful waiting (WW), in patients with localized or locally advanced prostate cancer.
OriginalsprogEngelsk
TidsskriftJournal of Urology
Vol/bind172
Udgave nummer5 Pt 1
Sider (fra-til)1871-6
Antal sider6
ISSN0022-5347
StatusUdgivet - 1 nov. 2004

ID: 34081212